CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Experts Exploring Gene Therapies To Treat Cardiomyopathieson August 5, 2022 at 6:37 am
In a recent press release, Professor Sir Nilesh, the medical director at the British Heart Foundation said, “Once successful, the same gene editing innovations could be used to treat a whole range of ...
- Gene-edited cattle can provide future answers to today’s challengeson August 4, 2022 at 1:07 am
Gene-editing in cattle can potentially provide a lot of answers to the challenges cattle producers face today in the pasture and in the feedlot. Experts say the technology could help produce cattle ...
- Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?on August 3, 2022 at 6:08 pm
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
- Labrador dogs gene edited and cloned to prevent inherited hip diseaseon August 3, 2022 at 9:16 am
CRISPR gene editing has been used to try to prevent a genetic disorder in dogs for the first time, in this case a common condition called hip dysplasia ...
- ARTISAN LAUNCHES STAR-CRISPR™ TO PROVIDE BROAD GENE EDITING ACCESS FOR DRUG DISCOVERY AND DEVELOPMENTon August 2, 2022 at 9:51 am
Artisan Bio, a world-leader in CRISPR genome engineering technology, today announced the launch of its CRISPR-based 1-stop shop developed from the company's proprietary STAR-CRISPR™ platform. Artisan ...
- CRISPR Technology Breaks New Ground with Edits to Gene that Regulates Cholesterolon August 2, 2022 at 8:54 am
In 2013, scientists described a method for editing the genome of eukaryotic cells (such at those found in humans) using CRISPR technology. Since then, the | Clinical And Molecular Dx ...
- Brief: Exit for CoverCress as Bayer buys majority stake in gene-edited cover crop startupon August 2, 2022 at 4:54 am
The deal will enable CoverCress to further commercialize its winter oilseed cover crop and bring farmers another source of revenue.
- CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Researchon August 1, 2022 at 9:40 am
The global CRISPR Gene Editing Market was valued USD 1.09 billion in 2021 and is predicted to reach USD 14.80 billion by 2030, increasing at a CAGR of 29.80% from 2022 to 2030. North America dominated ...
- FDA halts testing of Beam’s base editing cancer therapyon August 1, 2022 at 5:52 am
The regulator has put on hold human testing of a blood cancer treatment known as BEAM-201, one of two that the biotech aims to bring to clinical trials this year.
- Gene Editing Tools Market is expected to register 18.8% CAGR between 2022 and 2029on July 26, 2022 at 1:45 am
According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 481.3 Mn in terms of value in 2022. The report on the gene editing tools ...
via Bing News